Council Of Europe Turns The Screw On Drug Pricing, Conflicts Of Interest - And More
This article was originally published in SRA
The pressure on pharmaceutical companies to justify the prices they charge for new drugs just seems to keep on growing. The Council of Europe, a human rights organization encompassing no less than 47 member countries, has said that greater transparency is needed on the actual R&D costs that lie beneath "exorbitant" prices of some medicines, particularly those for cancer and hepatitis C1.
Register for our free email digests: